Next Article in Journal
Emerging Trends in AI and Radiomics for Bladder, Kidney, and Prostate Cancer: A Critical Review
Previous Article in Journal
Tissue-Based Diagnostic Biomarkers of Aggressive Variant Prostate Cancer: A Narrative Review
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Cancers
Volume 16
Issue 4
10.3390/cancers16040809
cancers-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Hormone Replacement Therapy and Risks of Various Cancers in Postmenopausal Women with De Novo or a History of Endometriosis

by
Hee Joong Lee
1,
Banghyun Lee
2,*,
Hangseok Choi
3,
Minkyung Lee
2,
Kyungjin Lee
2,
Tae Kyoung Lee
2,
Sung Ook Hwang
2 and
Yong Beom Kim
4
1
Department of Obstetrics & Gynecology, Uijeongbu St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul 11765, Republic of Korea
2
Department of Obstetrics and Gynecology, Inha University Hospital, Inha University College of Medicine, Incheon 22332, Republic of Korea
3
Medical Science Research Center, Korea University College of Medicine, Seoul 02841, Republic of Korea
4
Department of Obstetrics and Gynecology, Seoul National University Bundang Hospital, Seongnam-si 13620, Republic of Korea
*
Author to whom correspondence should be addressed.
Cancers 2024, 16(4), 809; https://doi.org/10.3390/cancers16040809
Submission received: 19 January 2024 / Revised: 8 February 2024 / Accepted: 14 February 2024 / Published: 16 February 2024
(This article belongs to the Section Cancer Epidemiology and Prevention)
Browse Figure
Review Reports Versions Notes

Abstract

:

Simple Summary

Hormone replacement therapy (HRT) is used to improve the climacteric symptoms in postmenopausal women with a history of endometriosis. However, the impact of HRT on the malignant transformations of postmenopausal endometriosis is unclear. Therefore, this study examined the effects of HRT on the occurrences of various cancers in postmenopausal women with de novo or a history of endometriosis using the data from the Korean nationwide cohort study. In this study, the use of HRT increased the risk of uterine cancer, but it did not increase the risks of another nine cancers. Interestingly, the use of combined estrogen and progesterone reduced the risks of liver and thyroid cancers, and the use of estrogen alone reduced the risks of breast and lung cancers. Tibolone use was not associated with the risks of ten cancers. These results provide useful information on the use of HRT in women with de novo or a history of endometriosis.

Abstract

This study examined the impact of hormone replacement therapy (HRT) on the occurrence of various cancers in postmenopausal women with de novo or a history of endometriosis. In the datasets for ten cancers (cervical, uterine, ovarian, breast, colon, gastric, liver, lung, pancreatic, and thyroid), women who received HRT (the HRT group) and those who did not (the control group) were selected by a 1:1 matching with those who met the study criteria. In the dataset for each cancer, the incidence of each cancer was very low (0.2% to 1.5% in the HRT group and 0.2% to 1.3% in the control group). The duration of HRT was 1.3 ± 2.1 years. After adjusting for co-variables, HRT was a significant risk factor for uterine cancer (p < 0.05). However, the risk of liver cancer decreased significantly with duration of HRT (p < 0.05). Moreover, combined estrogen and progesterone decreased the risks of liver and thyroid cancers significantly (p < 0.05), and estrogen alone decreased the risks of breast and lung cancers significantly (p < 0.05). Tibolone was not associated with the risk of any of the cancers assessed. These results can help guide the use of HRT in women with de novo or a history of endometriosis.

1. Introduction

Endometriosis is a chronic, recurrent, benign disease involving the presence of endometrial tissue outside the uterine cavity. Endometriosis occurs mostly in the pelvic cavity, but extrapelvic endometriosis can occur, albeit rarely, in distant sites from gynecological organs, depending on the location of endometrial tissue implantation [1].
Endometriosis affects women from premenarche to postmenopause [2,3]. The incidence of endometriosis is 6–10% and 2–4% in premenopausal and postmenopausal women, respectively [4]. The risk of a malignant transformation of endometriotic lesions is approximately 1% [4,5,6]. Endometriosis recurrence or malignant transformations can occur in the postmenopausal period [2,7,8].
Many case reports and series have revealed the recurrence or malignant transformation of endometriosis after hormone replacement therapy (HRT), particularly with estrogen alone in postmenopausal women with a history of endometriosis [2,9,10,11,12,13]. In contrast, one randomized controlled trial (RCT) (n = 172) reported that HRT did not increase the recurrence of endometriosis significantly in postmenopausal women with a history of endometriosis [14]. Moreover, in one retrospective study (n = 93), estrogen alone showed a trend toward an increased risk of a malignant transformation of endometrioma [15]. In addition, in one RCT (n = 21), tibolone showed a better pelvic pain rate compared to estrogen with or without progesterone in women with residual pelvic endometriosis, but the difference was not significant [16]. Therefore, the impact of HRT on the risks of endometriosis recurrence and malignant transformation in postmenopausal women with a history of endometriosis is unclear owing to the lack of high-quality studies [2]. On the other hand, based on low-quality evidence, combined estrogen and progesterone are currently recommended to improve menopausal symptoms in postmenopausal women with a history of endometriosis [9,17]. Tibolone can also be considered [9].
The relationships between HRT and the malignant transformation of de novo or recurrent postmenopausal endometriosis are still unclear. Moreover, the malignant transformations of endometriosis might occur in pelvic and extrapelvic endometriosis. Therefore, this nationwide cohort study examined the effects of HRT on the occurrences of various cancers in postmenopausal women with de novo or a history of endometriosis using Korean health insurance review and assessment service (HIRA) data.

2. Materials and Methods

The National Health Service, a universal health coverage system in the Republic of Korea, covers ~98% of the population [18]. Most of the National Health Insurance Service data are shared by the HIRA. Patients with cancer receive additional medical payment discounts. Hence, the diagnosis codes for cancer in medical information are highly accurate. This study evaluated the claims data of women diagnosed with endometriosis according to the diagnostic codes in the HIRA between 1 January 2007 and 31 December 2022. The Institutional Review Board of The Catholic Medical Center at the Catholic University of Korea (No. UC23ZISI0019) approved this study on 9 March 2023. The HIRA dataset uses anonymous identification codes to protect personal information, as the Bioethics and Safety Act of South Korea requires. Therefore, the requirement for informed consent for the patients included in the data was waived.
This study used the International Classification of Diseases 10th revision (ICD-10), Korea Health Insurance Medical Care Expenses (2017 and 2019 versions), and HIRA Drug Ingredients Codes for the selection and analysis of subjects. Women with endometriosis were defined as having the diagnostic codes for endometriosis (N80x) with the surgery codes within 60 days before or after an initial diagnostic code. Women who received HRT (HRT group) were defined as women who received HRT prescriptions for ≥28 days, whereas those who did not (control group) were defined as women who did not receive a prescription for HRT. The following exclusion criteria were used to select eligible patients: women ≤ 49 years old at the last clinic visit; women diagnosed with endometriosis during the washout period (between 1 January 2007 and 31 December 2007); women diagnosed with each cancer before the date of the first diagnostic code for endometriosis. Women with or without HRT were identified using 1:1 matching according to the age at the last clinic visit in the dataset for each cancer. Women diagnosed with each cancer before receiving HRT and those diagnosed with each cancer within one year of HRT receipt were excluded from the HRT group in the dataset for each cancer. An additional exclusion criterion was women diagnosed with each cancer before menopause or within one year after menopause. The date HRT was started in the HRT group was considered the date of menopause. The date of menopause in the control group was defined by matching with the HRT group. Accordingly, this study excluded women diagnosed with each cancer in the HRT or control groups before HRT or menopause or within one year after HRT or menopause (Figure 1 and Table S1 in Supplementary Materials file). The dataset for each cancer was independently created and not associated with datasets for other cancers. Therefore, women diagnosed with each cancer during the creation of the dataset for each cancer and those diagnosed with each cancer from the dataset for each cancer were candidates for datasets for other cancers.
Women with each cancer were defined as having one or more diagnostic codes for the following cancers: cervical cancer (C53x), uterine cancer (C54x), ovarian cancer (C56x), breast cancer (C50x), colon cancer (C18x), gastric cancer (C16x), liver cancer (C22x), lung cancer (C33 and C34x), pancreatic cancer (C25), and thyroid cancer (C73). Bladder cancer (C67.x), bone cancer (C41.x), brain cancer (C71.x), esophageal cancer (C15.x), leukemia (C91.x, C92.x, C93.x, C94.x, and C95.x), melanoma (C43.x), mesothelioma (C45.x), non-Hodgkin lymphoma (C82.x, C83.x, C84.x, C85.x, and C86.x), oral cancer (C05.x and C06.x), and renal cancer (C64.0 and C65.0) were excluded from the analysis because the incidence of cancer in eligible dataset for each cancer was zero or extremely low (0.05% to 0.09%). The medical insurance type was defined as low socioeconomic status (SES) when it was medical protection. The Charlson Comorbidity Index (CCI) was obtained using the diagnostic code from the date of the last clinic visit to the year before [19]. The methods of surgery for endometriosis included ovarian cystectomy, bilateral or unilateral salpingo-oophorectomy (BSO or USO), hysterectomy, or fulguration. Surgery was defined as the codes for those surgeries and a concurrent diagnostic code for endometriosis or surgery codes within 60 days before or after an initial diagnostic code for endometriosis. Hormone therapy was defined using prescription codes, such as combined estrogen and progesterone, estrogen alone, or tibolone.

Statistical Analyses

In the HRT and control groups of the dataset for each cancer, women were considered homogenous if they were the same age at the last clinic visits. Therefore, the two groups were 1:1 matched for age. Logistic regression analysis, adjusted for the confounding factors or not, was conducted to determine the relationships between the independent risk factors and each group in the dataset for each cancer. In the dataset for each cancer, the association between the two groups and time-to-event data was analyzed using the Kaplan–Meier and Cox proportional-hazards regression models. Cox multiple regression was used to control for confounding variables. An independent t-test was used to analyze the continuous variable in the dataset for each cancer. All statistical analyses were conducted using two-tailed tests, and a p value < 0.05 was considered significant. SAS version 9.4 (SAS Institute Inc., Cary, NC, USA) was used to explore and modify big data, and the analysis was conducted using R version 3.5.1 (R Foundation for Statistical Computing, Vienna, Austria) [20,21].

3. Results

The data of 135,379 women with a diagnostic code for endometriosis first registered by the HIRA between 2007 and 2022 were extracted in the initial study. Women in this group who met the study eligibility criteria were independently selected in ten datasets for ten cancers (Figure 1). Furthermore, in the dataset for each cancer, these were assigned by 50.0% to the HRT and control groups, respectively.

3.1. Characteristics of Datasets for Various Cancers

Tables 1 and Table S1 list the baseline characteristics of the datasets for the ten cancers.
The mean age at the last clinic visit in both groups was 55.5 ± 4.9 years in the dataset for each cancer (Table S2). In the dataset for each cancer, the mean ages at the endometriosis diagnosis ranged from 48.4 ± 6.1 to 48.5 ± 6.2 years and were significantly younger in the HRT group than in the control group (p < 0.001) (Table S2). The rates of hysterectomy for benign disease were significantly lower in the HRT group than in the control group in the dataset for each cancer (p < 0.001) (Table S2). In the dataset for each cancer, among the methods of surgery for endometriosis, the rates of ovarian cystectomy, BSO, or USO were significantly higher in the HRT group than in the control group. By contrast, the rate of hysterectomy was significantly lower in the HRT group than in the control group (p < 0.05) (Table S2). The number of surgeries for endometriosis was significantly higher in the HRT group than in the control group in the dataset for each cancer (p < 0.05) (Table S2). The mean duration of HRT was 1.3 ± 2.1 years in the dataset for each cancer (Table 1). Combined estrogen and progesterone, estrogen alone, and tibolone were used in approximately 34.7%, 48.8%, and 51.4% of the HRT group, respectively, in the dataset for each cancer (Table 1). In the dataset for each cancer, the rate of HRT use before and after the endometriosis diagnosis was approximately 26.0% and 74.0%, respectively (Table S2). Table S2 lists the SES and CCI at the last clinic visit and the distribution of patients according to the year of endometriosis diagnosis in the dataset for each cancer.

3.2. Incidences of Various Cancers

The incidence of each cancer was very low (0.2% to 1.5% in the HRT group and 0.2% to 1.3% in the control group). The receipt of HRT was not significantly associated with the incidence of each cancer (Table 2).

3.3. Risk Factors for Various Cancers

Multivariate analysis adjusted for the potential confounding variables revealed the following results. The risks of cervical, ovarian, colon, gastric, and lung cancers increased significantly with age at endometriosis diagnosis in the total population, the HRT group, and/or the control group (p < 0.05). By contrast, the risk of breast cancer decreased significantly with age at endometriosis diagnosis in the total population and the control group (p < 0.05). In addition, other cancers did not show associations with age at endometriosis diagnosis. Regarding the year of endometriosis diagnosis, the risks of cervical, uterine, and ovarian cancers increased significantly with time in the total population and both groups (p <0.001), whereas the risks of colon, gastric, liver, and lung cancers decreased significantly with time in total population, the HRT group, and/or the control group (p < 0.05). In addition, other cancers did not show associations with the year of an endometriosis diagnosis. The risks of uterine, ovarian, and thyroid cancers significantly increased as the number of surgeries for endometriosis increased in the total population, the HRT group, and/or the control group (p < 0.05), but the other cancers did not show associations with the number of surgeries for endometriosis. The risks of cervical, uterine, and ovarian cancers significantly decreased in women who had undergone a hysterectomy for benign disease in the total population, and both groups (p < 0.05), but the other cancers assessed did not show associations with a hysterectomy for benign disease (Table S3).
The receipt of HRT increased the risk of uterine cancer significantly (p < 0.05), but it was not associated with the risks of other cancers. According to the increase in HRT duration, the risk of liver cancer decreased significantly (p < 0.05), but other cancers did not show associations with the HRT duration. The receipt of combined estrogen and progesterone was significantly associated with a decrease in the risks of liver and thyroid cancers (p < 0.05), and the use of estrogen alone was significantly associated with a decrease in the risks of breast and lung cancers (p < 0.05). On the other hand, they were not associated with the risks of other cancers. The receipt of tibolone was not associated with the risk for each cancer (Table 3).

3.4. Characteristics of Various Cancers

In cervical and thyroid cancers, the times between the endometriosis diagnosis and cancer diagnosis were significantly shorter in the HRT group than in the control group. In contrast, in other cancers, those were similar in the HRT and control groups (Table S4). The mean times from HRT commencement to each cancer diagnosis ranged from 5.1 to 6.9 years (Table S5). The mean duration of HRT in women with each cancer ranged from 0.9 to 2.7 years (Table S6). The mean ages at each cancer diagnosis were significantly younger in the HRT group than in the control group (Table S7).

4. Discussion

In this study, postmenopausal women with a de novo or a history of endometriosis administered or not administered HRT had a low and similar incidence of the ten cancers evaluated. HRT increased the risk of uterine cancer according to multivariate analysis adjusted for confounding factors. Moreover, an increase in the duration of HRT reduces the risk of liver cancer. Moreover, the use of combined estrogen and progesterone reduced the risks of liver and thyroid cancers, and the use of estrogen alone reduced the risks of breast and lung cancers. Furthermore, the use of tibolone was not associated with the risks for ten cancers.
The average age of menopause generally ranges from ~50 and 51 years [22,23]. Therefore, this study excluded women aged ≤49 years at the last clinic visit. HRT is generally used to improve the quality of life in symptomatic postmenopausal women. In the present dataset for each cancer, based on the time sequence between endometriosis diagnosis and beginning of HRT, de novo postmenopausal endometriosis was observed in 26.0% of the women with HRT and a history of endometriosis was noted in 74.0% (Table S1).
In large-scale cohorts and a pooled analysis, endometriosis and HRT were associated with an increased risk of endometrial, ovarian, and breast cancers [24,25,26]. Moreover, HRT was associated with decreased risks of liver and colon cancers and did not influence gastric and pancreatic cancers [26]. Therefore, this study expected that postmenopausal women with de novo or a history of endometriosis who received HRT would show similar results to previous studies in relation to the risks of the above cancers compared to those who did not receive HRT. On the other hand, HRT increased the risk of only uterine cancer (Table 3).
In a large-scale cohort and meta and pooled analyses, the risks of endometrial cancer (in users of sequential-combined HRT with synthetic progestins) and ovarian cancer increased significantly with the duration of HRT (especially for durations of ≥10 years), but the use of estrogen alone for one to <10 years in women >50 years was not associated with the risk of ovarian cancer [27,28,29]. In the present study, the HRT duration was not a risk factor for endometrial and ovarian cancers in postmenopausal women with a de novo or a history of endometriosis, suggesting that a very short duration of HRT can be attributed. Instead, the risk of liver cancer decreased with the duration of HRT (Table 3). In the dataset for each cancer, the overall mean duration of HRT was similar to that in women with cancer (Table 1 and Table S6). Each cancer developed a mean of 3.8 to 5.6 years after stopping HRT (Table 1 and Table S5).
Based on previous studies and the ESHRE guidelines, combined estrogen and progesterone are recommended for symptomatic postmenopausal women with a history of endometriosis. On the other hand, estrogen alone is not recommended because of the high risk of malignant transformation [9,17]. In addition, tibolone is considered a safe hormonal treatment for postmenopausal women with a history of endometriosis [9,16]. In a nationwide cohort study (n = 290,186) analyzing HRT users, combined estrogen and progesterone were associated with increased risks of ovarian and breast cancers and a decreased risk of colon cancer. They did not influence endometrial, liver, gastric, and pancreatic cancers [26]. Moreover, estrogen alone and tibolone were associated with an increased risk of endometrial and breast cancers and a decreased risk of colon cancer. In addition, they did not influence ovarian (estrogen alone and tibolone), liver (estrogen alone), gastric (estrogen alone), and pancreatic cancers (estrogen alone) [26]. In two RCTs involving 27,347 postmenopausal women, combined estrogen and progesterone were associated with a higher risk of breast cancer than the placebo. In contrast, estrogen alone among women with prior hysterectomy was associated with a lower risk of breast cancer than placebo [30]. In the present study, when analyzed according to types of HRT medication, combined estrogen and progesterone, estrogen alone, and tibolone were not risk factors for ten cancers in postmenopausal women with de novo or a history of endometriosis. Moreover, combined estrogen and progesterone reduced the risks of liver and thyroid cancers, and estrogen alone reduced the risks of breast and lung cancers (Table 3). In a prior study, estrogen alone was identified as a risk factor for ovarian cancer in postmenopausal women (n = 10,304) with de novo or a history of endometriosis administered HRT and registered by HIRA between 2008 and 2020 [31]. This difference was attributed to the very low incidence of ovarian cancer (present study: 0.4%; prior study: 0.3%), even though the present ovarian cancer dataset included more patients (n = 14,724) registered during a longer period (2008 to 2022) compared to a previous study [31].
In the present dataset for each cancer, the ages at the endometriosis diagnosis ranged from a mean of 48.4 to 48.5 years (Table S2). Women who were diagnosed with endometriosis at an older age had an increased risk of colon, gastric, and lung cancers, which coincided with the fact that the incidence of those cancers increased with age based on the Korea Central Cancer Registry (KCCR), whereas women who were diagnosed with endometriosis at an older age had a decreased risk of breast cancer, which coincided with the fact that the incidence of this cancer decreased with age after the peak incidence at 45 to 49 years (KCCR) (Table S3) [32]. Moreover, women who were diagnosed with endometriosis at an older age had an increased risk of cervical and ovarian cancers (Table S3). However, the incidence of those cancers decreased with age after the peak incidence at 40 to 49 years and at 50 to 59 years, respectively (KCCR) [33,34].
In the present study, women who were more recently diagnosed with endometriosis had an increased risk of uterine and ovarian cancers, which coincided with a continued increase in the annual incidence of those cancers (KCCR), while women who were more recently diagnosed with endometriosis had a decreased risk of colon, gastric, liver, and lung cancers, which coincided with a continued decrease in the annual incidence of those cancers (KCCR) (Table S3) [34,35,36]. However, the risk of cervical cancer, with a consistent decrease in annual incidence (KCCR), has increased for women diagnosed with endometriosis more recently (Table S3) [33,35].
In a nationwide cohort study (n = 45,790), the incidences of endometrial and ovarian cancers increased with time after endometriosis diagnosis (standardized incidence ratios: endometrial cancer, 1.00 at one to four years and 1.37 at five to nine years post-diagnosis; ovarian cancer, 1.51 at one to four years and 1.78 at five to nine years post-diagnosis), but the incidence of breast cancer was not associated with the time since the endometriosis diagnosis [24]. In the present study, women who received HRT underwent more surgeries for endometriosis in the dataset for each cancer (Table S2). In addition, the risks of uterine, ovarian, and thyroid cancers increased as the number of surgeries for endometriosis increased, suggesting that the risks of those cancers increased with time since endometriosis diagnosis (Table S3).
Based on the guidelines for the management of endometriosis, combined endometriotic lesion resection and concomitant hysterectomy with or without BSO might reduce the recurrence rates of endometriosis compared to resection of endometriotic lesions alone [37]. In a nationwide cohort study (n = 155,972), the risk of colon cancer increased in women who underwent a hysterectomy alone compared to women who did not [38]. In the present dataset for each cancer, regardless of HRT use, a hysterectomy for benign disease reduced the risks of cervical, uterine, and ovarian cancers, suggesting that a hysterectomy has therapeutic effects via the removal of the uterus as well as reduction in the risk of endometriosis recurrence (Table S3).
In the present dataset for each cancer, women who received HRT had more surgeries for endometriosis and were diagnosed with endometriosis or each cancer at a younger age, suggesting that they might have been more concerned with their health and have had more tests (Tables S2 and S7).
This large-scale, nationwide, population-based cohort study was the first to examine the impact of HRT on the occurrences of various cancers in postmenopausal women with de novo or a history of endometriosis. The limitations of this study are as follows. First, the diseases and treatments were defined using the diagnostic and prescription codes without reviewing the medical records. Hence, a few women with incorrect codes might have been misdefined. Second, the time of menopause and the severity of endometriosis could not be determined in the population because of the characteristics of claims data. Therefore, the date when women in the HRT group first received HRT was defined as the date at menopause in both groups. Third, women diagnosed and managed with endometriosis before the start of the HIRA dataset and subsequently underwent recurrence of endometriosis might have been included. Fourth, the significance of the impacts of HRT on occurrences of the ten cancers in postmenopausal women with de novo or a history of endometriosis is limited because of the very low incidence of each cancer and the very short duration of HRT. Finally, the impact of HRT on only ten cancers can be analyzed because of the extremely low incidences of many cancers.

5. Conclusions

This large-scale Korean nationwide cohort study showed that HRT does not increase the risks of nine cancers except uterine cancer alone in postmenopausal women with de novo or a history of endometriosis. Moreover, combined estrogen and progesterone have benefits on the risks of liver and thyroid cancers, and estrogen alone has benefits on the risks of breast and lung cancers. These results provide clinically useful information to guide the use of HRT in postmenopausal women with de novo or a history of endometriosis. Nevertheless, large-scale studies will be needed to confirm these results.

Supplementary Materials

The following supporting information can be downloaded at https://www.mdpi.com/article/10.3390/cancers16040809/s1. Table S1: Data to extract eligible patients for the dataset for each cancer; Table S2: Characteristics of the dataset for each cancer according to HRT in women with postmenopausal endometriosis (HIRA claims data 2008–2022). A. Dataset for cervical cancer; B. Dataset for uterine cancer; C. Dataset for ovarian cancer; D. Dataset for breast cancer; E. Dataset for colon cancer; F. Dataset for gastric cancer; G. Dataset for liver cancer; H. Dataset for lung cancer; I. Dataset for pancreatic cancer; and J. Dataset for thyroid cancer; Table S3: Associations between the risk factors and various cancer occurrences according to HRT in women with postmenopausal endometriosis (HIRA claims data 2008–2022); Table S4: Time between an endometriosis diagnosis and various cancer diagnoses (years) (HIRA claims data 2008–2022); Table S5: Time between the beginning of HRT and various cancer diagnoses (years) (HIRA claims data 2008–2022); Table S6: Duration of HRT use in women with various cancers (years) (HIRA claims data 2008–2022); Table S7: Ages at various cancer diagnoses (years) (HIRA claims data 2008–2022).

Author Contributions

Conceptualization, H.J.L., B.L., M.L., K.L., T.K.L. and S.O.H.; methodology, H.J.L. and B.L.; software, H.J.L., B.L. and H.C.; validation, H.J.L. and B.L.; formal analysis, H.J.L., B.L. and H.C.; investigation, H.J.L., B.L., M.L., K.L. and T.K.L.; resources, H.J.L. and B.L.; data curation, H.J.L., B.L. and H.C.; writing—original draft preparation, H.J.L. and B.L.; writing—review and editing, H.J.L., B.L., H.C., M.L., K.L., T.K.L., S.O.H. and Y.B.K.; visualization, H.J.L. and B.L.; supervision, S.O.H. and Y.B.K.; project administration, B.L. All authors have read and agreed to the published version of the manuscript.

Funding

This work was supported by the INHA UNIVERSITY Research Grant.

Institutional Review Board Statement

The study was approved by the Institutional Review Board of The Catholic Medical Center at the Catholic University of Korea (No. UC23ZISI0019), which waived the requirement for informed consent.

Informed Consent Statement

Informed consent was not required due to the use of anonymized data and the retrospective nature of the study.

Data Availability Statement

The data that support the findings of this study are available from the Health Insurance Review and Assessment Service (HIRA), but restrictions apply to the availability of these data, which were used under license for the current study and so are not publicly available. Data are available from the authors upon reasonable request and with permission of the HIRA.

Acknowledgments

The authors wish to thank the Health Insurance Review and Assessment Service for providing data (HIRA-M20230303003) for this study.

Conflicts of Interest

The authors declare no conflicts of interest.

Abbreviations

BSO: bilateral salpingo-oophorectomy; CCIs: Charlson Comorbidity Indices; CI: confidence interval; HR: hazard ratio; HIRA: Health Insurance Review and Assessment Service; HRT: hormone replacement therapy; ICD-10: the 10th revision of the International Statistical Classification of Diseases and Related Health Problems; KCCR: Korea Central Cancer Registry; SES: socioeconomic status; USO: unilateral salpingo-oophorectomy.

References

  1. Machairiotis, N.; Stylianaki, A.; Dryllis, G.; Zarogoulidis, P.; Kouroutou, P.; Tsiamis, N.; Katsikogiannis, N.; Sarika, E.; Courcoutsakis, N.; Tsiouda, T.; et al. Extrapelvic endometriosis: A rare entity or an under diagnosed condition? Diagn. Pathol. 2013, 8, 194. [Google Scholar] [CrossRef] [PubMed]
  2. Gemmell, L.C.; Webster, K.E.; Kirtley, S.; Vincent, K.; Zondervan, K.T.; Becker, C.M. The management of menopause in women with a history of endometriosis: A systematic review. Hum. Reprod. Update 2017, 23, 481–500. [Google Scholar] [CrossRef] [PubMed]
  3. Batt, R.E.; Mitwally, M.F. Endometriosis from thelarche to midteens: Pathogenesis and prognosis, prevention and pedagogy. J. Pediatr. Adolesc. Gynecol. 2003, 16, 337–347. [Google Scholar] [CrossRef] [PubMed]
  4. Giannella, L.; Marconi, C.; Di Giuseppe, J.; Delli Carpini, G.; Fichera, M.; Grelloni, C.; Giuliani, L.; Montanari, M.; Insinga, S.; Ciavattini, A. Malignant Transformation of Postmenopausal Endometriosis: A Systematic Review of the Literature. Cancers 2021, 13, 4026. [Google Scholar] [CrossRef]
  5. Gadducci, A.; Lanfredini, N.; Tana, R. Novel insights on the malignant transformation of endometriosis into ovarian carcinoma. Gynecol. Endocrinol. 2014, 30, 612–617. [Google Scholar] [CrossRef]
  6. Wang, C.T.; Wang, D.B.; Liu, K.R.; Li, Y.; Sun, C.X.; Guo, C.S.; Ren, F. Inducing malignant transformation of endometriosis in rats by long-term sustaining hyperestrogenemia and type II diabetes. Cancer Sci. 2015, 106, 43–50. [Google Scholar] [CrossRef]
  7. Hickman, T.N.; Namnoum, A.B.; Hinton, E.L.; Zacur, H.A.; Rock, J.A. Timing of estrogen replacement therapy following hysterectomy with oophorectomy for endometriosis. Obstet. Gynecol. 1998, 91, 673–677. [Google Scholar] [CrossRef] [PubMed]
  8. Morotti, M.; Remorgida, V.; Venturini, P.L.; Ferrero, S. Endometriosis in menopause: A single institution experience. Arch. Gynecol. Obstet. 2012, 286, 1571–1575. [Google Scholar] [CrossRef]
  9. Zanello, M.; Borghese, G.; Manzara, F.; Degli Esposti, E.; Moro, E.; Raimondo, D.; Abdullahi, L.O.; Arena, A.; Terzano, P.; Meriggiola, M.C.; et al. Hormonal Replacement Therapy in Menopausal Women with History of Endometriosis: A Review of Literature. Medicina 2019, 55, 477. [Google Scholar] [CrossRef]
  10. Petersen, V.C.; Underwood, J.C.; Wells, M.; Shepherd, N.A. Primary endometrioid adenocarcinoma of the large intestine arising in colorectal endometriosis. Histopathology 2002, 40, 171–176. [Google Scholar] [CrossRef]
  11. Leiserowitz, G.S.; Gumbs, J.L.; Oi, R.; Dalrymple, J.L.; Smith, L.H.; Ryu, J.; Scudder, S.; Russell, A.H. Endometriosis-related malignancies. Int. J. Gynecol. Cancer 2003, 13, 466–471. [Google Scholar] [CrossRef]
  12. Soliman, N.F.; Evans, A.J. Malignancy arising in residual endometriosis following hysterectomy and hormone replacement therapy. J. Br. Menopause Soc. 2004, 10, 123–124. [Google Scholar] [CrossRef]
  13. Karanjgaokar, V.C.; Murphy, D.J.; Samra, J.S.; Mann, C.H. Malignant transformation of residual endometriosis after hysterectomy: A case series. Fertil. Steril. 2009, 92, 2037.e19–2037.e21. [Google Scholar] [CrossRef] [PubMed]
  14. Marjoribanks, J.; Farquhar, C.; Roberts, H.; Lethaby, A.; Lee, J. Long-term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst. Rev. 2017, 1, Cd004143. [Google Scholar] [CrossRef]
  15. Zanetta, G.M.; Webb, M.J.; Li, H.; Keeney, G.L. Hyperestrogenism: A relevant risk factor for the development of cancer from endometriosis. Gynecol. Oncol. 2000, 79, 18–22. [Google Scholar] [CrossRef] [PubMed]
  16. Fedele, L.; Bianchi, S.; Raffaelli, R.; Zanconato, G. Comparison of transdermal estradiol and tibolone for the treatment of oophorectomized women with deep residual endometriosis. Maturitas 1999, 32, 189–193. [Google Scholar] [CrossRef]
  17. Becker, C.M.; Bokor, A.; Heikinheimo, O.; Horne, A.; Jansen, F.; Kiesel, L.; King, K.; Kvaskoff, M.; Nap, A.; Petersen, K.; et al. ESHRE guideline: Endometriosis. Hum. Reprod. Open 2022, 2022, hoac009. [Google Scholar] [CrossRef]
  18. Kim, L.; Kim, J.A.; Kim, S. A guide for the utilization of Health Insurance Review and Assessment Service National Patient Samples. Epidemiol Health 2014, 36, e2014008. [Google Scholar] [CrossRef] [PubMed]
  19. Quan, H.; Li, B.; Couris, C.M.; Fushimi, K.; Graham, P.; Hider, P.; Januel, J.M.; Sundararajan, V. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am. J. Epidemiol. 2011, 173, 676–682. [Google Scholar] [CrossRef]
  20. SAS Institute Inc. SAS, 9.4 ed.; SAS Institute Inc: Cary, NC, USA, 2020.
  21. Team, R.C. R: A Language and Environment for Statistical Computing; 3.5.1 ed.; R Foundation for Statistical Computing: Vienna, Austria, 2022. [Google Scholar]
  22. Kim, Y.T.; Cha, C.; Lee, M.R. Factors related to age at menopause among Korean women: The Korean Longitudinal Survey of Women and Families. Menopause 2019, 26, 492–498. [Google Scholar] [CrossRef]
  23. Daan, N.M.; Fauser, B.C. Menopause prediction and potential implications. Maturitas 2015, 82, 257–265. [Google Scholar] [CrossRef] [PubMed]
  24. Mogensen, J.B.; Kjær, S.K.; Mellemkjær, L.; Jensen, A. Endometriosis and risks for ovarian, endometrial and breast cancers: A nationwide cohort study. Gynecol. Oncol. 2016, 143, 87–92. [Google Scholar] [CrossRef]
  25. Pearce, C.L.; Templeman, C.; Rossing, M.A.; Lee, A.; Near, A.M.; Webb, P.M.; Nagle, C.M.; Doherty, J.A.; Cushing-Haugen, K.L.; Wicklund, K.G.; et al. Association between endometriosis and risk of histological subtypes of ovarian cancer: A pooled analysis of case-control studies. Lancet Oncol. 2012, 13, 385–394. [Google Scholar] [CrossRef] [PubMed]
  26. Simin, J.; Tamimi, R.; Lagergren, J.; Adami, H.O.; Brusselaers, N. Menopausal hormone therapy and cancer risk: An overestimated risk? Eur. J. Cancer 2017, 84, 60–68. [Google Scholar] [CrossRef] [PubMed]
  27. Trabert, B.; Wentzensen, N.; Yang, H.P.; Sherman, M.E.; Hollenbeck, A.R.; Park, Y.; Brinton, L.A. Is estrogen plus progestin menopausal hormone therapy safe with respect to endometrial cancer risk? Int. J. Cancer 2013, 132, 417–426. [Google Scholar] [CrossRef] [PubMed]
  28. Beral, V.; Gaitskell, K.; Hermon, C.; Moser, K.; Reeves, G.; Peto, R. Menopausal hormone use and ovarian cancer risk: Individual participant meta-analysis of 52 epidemiological studies. Lancet 2015, 385, 1835–1842. [Google Scholar] [CrossRef] [PubMed]
  29. Lee, A.W.; Ness, R.B.; Roman, L.D.; Terry, K.L.; Schildkraut, J.M.; Chang-Claude, J.; Doherty, J.A.; Menon, U.; Cramer, D.W.; Gayther, S.A.; et al. Association Between Menopausal Estrogen-Only Therapy and Ovarian Carcinoma Risk. Obstet. Gynecol. 2016, 127, 828–836. [Google Scholar] [CrossRef]
  30. Chlebowski, R.T.; Anderson, G.L.; Aragaki, A.K.; Manson, J.E.; Stefanick, M.L.; Pan, K.; Barrington, W.; Kuller, L.H.; Simon, M.S.; Lane, D.; et al. Association of Menopausal Hormone Therapy with Breast Cancer Incidence and Mortality during Long-term Follow-up of the Women’s Health Initiative Randomized Clinical Trials. JAMA 2020, 324, 369–380. [Google Scholar] [CrossRef]
  31. Lee, H.J.; Lee, B.; Choi, H.; Kim, T.; Kim, Y.; Kim, Y.B. Impact of Hormone Replacement Therapy on Risk of Ovarian Cancer in Postmenopausal Women with De Novo Endometriosis or a History of Endometriosis. Cancers 2023, 15, 1708. [Google Scholar] [CrossRef]
  32. Jung, K.W.; Kang, M.J.; Park, E.H.; Yun, E.H.; Kim, H.J.; Kong, H.J.; Im, J.S.; Seo, H.G. Prediction of Cancer Incidence and Mortality in Korea, 2023. Cancer Res. Treat. 2023, 55, 400–407. [Google Scholar] [CrossRef]
  33. Suh, D.H.; Ha, H.I.; Lee, Y.J.; Lim, J.; Won, Y.J.; Lim, M.C. Incidence and treatment outcomes of uterine cervical cancer in Korea 1999–2018 from the national cancer registry. J. Gynecol. Oncol. 2023, 34, e39. [Google Scholar] [CrossRef] [PubMed]
  34. Ha, H.I.; Kim, J.H.; Lim, J.; Song, Y.J.; Won, Y.J.; Lim, M.C. Incidence and treatment outcomes of ovarian carcinosarcoma from the national cancer registry of Korea. J. Gynecol. Oncol. 2024, 35, e31. [Google Scholar] [CrossRef] [PubMed]
  35. Yun, B.S.; Park, E.H.; Ha, J.; Lee, J.Y.; Lee, K.H.; Lee, T.S.; Lee, K.J.; Kim, Y.J.; Jung, K.W.; Roh, J.W. Incidence and survival of gynecologic cancer including cervical, uterine, ovarian, vaginal, vulvar cancer and gestational trophoblastic neoplasia in Korea, 1999–2019: Korea Central Cancer Registry. Obstet. Gynecol. Sci. 2023, 66, 545–561. [Google Scholar] [CrossRef] [PubMed]
  36. Park, E.H.; Kang, M.J.; Jung, K.W.; Park, E.H.; Yun, E.H.; Kim, H.J.; Kong, H.J.; Cho, C.K.; Im, J.S.; Seo, H.G. Regional disparities in major cancer incidence in Korea, 1999–2018. Epidemiol. Health 2023, 45, e2023089. [Google Scholar] [CrossRef]
  37. Collinet, P.; Fritel, X.; Revel-Delhom, C.; Ballester, M.; Bolze, P.A.; Borghese, B.; Bornsztein, N.; Boujenah, J.; Brillac, T.; Chabbert-Buffet, N.; et al. Management of endometriosis: CNGOF/HAS clinical practice guidelines—Short version. J. Gynecol. Obstet. Hum. Reprod. 2018, 47, 265–274. [Google Scholar] [CrossRef]
  38. Yuk, J.; Yang, S.W.; Yoon, S.H.; Kim, M.H.; Seo, Y.S.; Lee, Y.; Kim, J.; Yang, K.; Gwak, G.; Cho, H. The increased risk of colorectal cancer in the women who underwent hysterectomy from the South Korean National Health Insurance Database. BMC Womens Health 2023, 23, 519. [Google Scholar] [CrossRef]
Cancers 16 00809 g001
Figure 1. Flow chart for extracting eligible patients. The datasets for each cancer include a dataset for cervical cancer, a dataset for uterine cancer, a dataset for ovarian cancer, a dataset for breast cancer, a dataset for colon cancer, a dataset for gastric cancer, a dataset for liver cancer, a dataset for lung cancer, a dataset for pancreatic cancer, and a dataset for thyroid cancer.
Figure 1. Flow chart for extracting eligible patients. The datasets for each cancer include a dataset for cervical cancer, a dataset for uterine cancer, a dataset for ovarian cancer, a dataset for breast cancer, a dataset for colon cancer, a dataset for gastric cancer, a dataset for liver cancer, a dataset for lung cancer, a dataset for pancreatic cancer, and a dataset for thyroid cancer.
Cancers 16 00809 g001
Table 1. Characteristics of the datasets for various cancers related to HRT in women with postmenopausal endometriosis (HIRA claims data 2008–2022).
Table 1. Characteristics of the datasets for various cancers related to HRT in women with postmenopausal endometriosis (HIRA claims data 2008–2022).
Duration of HRT
(Years)		Types of HRT Medication
Combined Estrogen
and Progesterone		Estrogen AloneTibolone
Dataset for cervical cancer1.3 ± 2.15093 (34.6)7185 (48.9)7551 (51.4)
Dataset for uterine cancer1.3 ± 2.15077 (34.7)7151 (48.8)7526 (51.4)
Dataset for ovarian cancer1.3 ± 2.15117 (34.7)7197 (48.8)7584 (51.4)
Dataset for breast cancer1.3 ± 2.15069 (34.8)7127 (48.9)7490 (51.4)
Dataset for colon cancer1.3 ± 2.15106 (34.6)7190 (48.8)7576 (51.4)
Dataset for gastric cancer1.3 ± 2.15109 (34.7)7181 (48.8)7557 (51.3)
Dataset for liver cancer1.3 ± 2.15098 (34.6)7184 (48.8)7576 (51.4)
Dataset for lung cancer1.3 ± 2.15127 (34.6)7233 (48.8)7610 (51.4)
Dataset for pancreatic cancer1.3 ± 2.15107 (34.7)7180 (48.8)7570 (51.4)
Dataset for thyroid cancer1.3 ± 2.14927 (34.8)6916 (48.8)7289 (51.4)
HIRA, health insurance review and assessment service; HRT, hormone replacement therapy. All values are expressed as mean ± standard deviation or number (%).
Table 2. Incidences of various cancers according to HRT in women with postmenopausal endometriosis (HIRA claims data 2008–2022).
Table 2. Incidences of various cancers according to HRT in women with postmenopausal endometriosis (HIRA claims data 2008–2022).
Total
(100.0%)		HRT (−)
(50.0%)		HRT (+)
(50.0%)		Adjusted OR
(95% CI) a		p Value a
Cervical cancer
 Negative29,334 (99.7)14,688 (99.7)14,666 (99.7)ref0.437
 Positive78 (0.3)38 (0.3)40 (0.3)1.195 (0.762, 1.873)
Uterine cancer
 Negative29,126 (99.4)14,567 (99.5)14,559 (99.4)ref0.102
 Positive168 (0.6)80 (0.6)88 (0.6)1.295 (0.95, 1.766)
Ovarian cancer
 Negative29,332 (99.6)14,663 (99.6)14,669 (99.6)ref0.94
 Positive116 (0.4)61 (0.4)55 (0.4)0.986 (0.682, 1.426)
Breast cancer
 Negative28,754 (98.6)14,389 (98.7)14,365 (98.6)ref0.511
 Positive396 (1.4)186 (1.3)210 (1.4)1.069 (0.876, 1.306)
Colon cancer
 Negative29,364 (99.6)14,686 (99.7)14,678 (99.6)ref0.676
 Positive106 (0.4)49 (0.3)57 (0.4)1.086 (0.739, 1.595)
Gastric cancer
 Negative29,453 (99.8)14,727 (99.8)14,726 (99.8)ref0.884
 Positive65 (0.2)32 (0.2)33 (0.2)0.964 (0.591, 1.572)
Liver cancer
 Negative29,328 (99.5)14,662 (99.5)14,666 (99.6)ref0.485
 Positive138 (0.5)71 (0.5)67 (0.5)0.887 (0.634, 1.242)
Lung cancer
 Negative29,543 (99.7)14,770 (99.7)14,773 (99.7)ref0.47
 Positive81 (0.3)42 (0.3)39 (0.3)0.851 (0.548, 1.32)
Pancreatic cancer
 Negative29,326 (99.6)14,667 (99.6)14,659 (99.6)ref0.666
 Positive122 (0.4)57 (0.4)65 (0.4)1.082 (0.756, 1.548)
Thyroid cancer
 Negative27,986 (98.7)14,017 (98.9)13,969 (98.5)ref0.072
 Positive370 (1.3)161 (1.1)209 (1.5)1.211 (0.983, 1.491)
CI, confidence interval; HIRA, health insurance review and assessment service; HRT, hormone replacement therapy; OR, odds ratio; ref, reference. Values are expressed as numbers (%). a The data were adjusted for age at endometriosis diagnosis, year of endometriosis diagnosis, number of surgeries for endometriosis, and hysterectomy for benign disease.
Table 3. Associations of HRT with various cancer occurrences in women with postmenopausal endometriosis (HIRA claims data 2008–2022).
Table 3. Associations of HRT with various cancer occurrences in women with postmenopausal endometriosis (HIRA claims data 2008–2022).
Use of HRTDuration of HRT
per 1 Year		Types of HRT Medication
Combined Estrogen and ProgesteroneEstrogen aloneTibolone
Adjusted HR (95% CI) ap Value aAdjusted HR (95% CI) bp Value bAdjusted HR (95% CI) bp Value bAdjusted HR (95% CI) bp Value bAdjusted HR (95% CI) bp Value b
Total
(100.0%)
Cervical cancer1.377 (0.874, 2.169)0.168
Uterine cancer1.542 (1.129, 2.106)0.007
Ovarian cancer1.15 (0.791, 1.672)0.465
Breast cancer1.058 (0.863, 1.297)0.590
Colon cancer1.03 (0.697, 1.522)0.883
Gastric cancer0.902 (0.55, 1.480)0.684
Liver cancer0.831 (0.59, 1.172)0.292
Lung cancer0.795 (0.508, 1.243)0.314
Pancreatic cancer1.059 (0.735, 1.527)0.759
Thyroid cancer1.187 (0.961, 1.467)0.113
HRT (+)
(50.0%)
Cervical cancer 0.818 (0.655, 1.022)0.0771.903 (0.922, 3.929)0.0821.053 (0.52, 2.134)0.8860.619 (0.284, 1.351)0.229
Uterine cancer 0.944 (0.856, 1.042)0.2541.056 (0.651, 1.725)0.8160.728 (0.447, 1.186)0.2030.652 (0.386, 1.098)0.108
Ovarian cancer 0.979 (0.876, 1.095)0.7140.987 (0.549, 1.774)0.9641.15 (0.627, 2.109)0.6520.933 (0.499, 1.742)0.827
Breast cancer 0.977 (0.915, 1.044)0.4970.804 (0.581, 1.111)0.1860.715 (0.517, 0.987)0.0420.8 (0.566, 1.13)0.205
Colon cancer 0.988 (0.894, 1.093)0.8191.713 (0.982, 2.989)0.0581.333 (0.761, 2.335)0.3151.47 (0.826, 2.615)0.190
Gastric cancer 1.099 (0.986, 1.225)0.0880.885 (0.42, 1.864)0.7480.986 (0.458, 2.125)0.9720.990 (0.446, 2.201)0.981
Liver cancer 0.378 (0.203, 0.702)0.0020.378 (0.203, 0.702)0.0021.052 (0.588, 1.883)0.8651.048 (0.571, 1.926)0.879
Lung cancer 1.018 (0.9, 1.151)0.7821.204 (0.565, 2.579)0.6260.373 (0.174, 0.8)0.0110.823 (0.370, 1.831)0.633
Pancreatic cancer 1.029 (0.933, 1.135)0.570.693 (0.392, 1.226)0.2080.805 (0.453, 1.431)0.4600.772 (0.421, 1.415)0.402
Thyroid cancer 0.984 (0.923, 1.049)0.6230.669 (0.484, 0.925)0.0150.971 (0.703, 1.341)0.8570.891 (0.634, 1.251)0.504
CI, confidence interval; HIRA, health insurance review and assessment service; HR, hazard ratio; HRT, hormone replacement therapy. a The data were adjusted for age at endometriosis diagnosis, year of endometriosis diagnosis, number of surgeries for endometriosis, hysterectomy for benign disease, and HRT. b The data were adjusted for age at endometriosis diagnosis, year of endometriosis diagnosis, number of surgeries for endometriosis, hysterectomy for benign disease, duration of HRT, and types of HRT medication. The red fonts show the statistically significant data.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Lee, H.J.; Lee, B.; Choi, H.; Lee, M.; Lee, K.; Lee, T.K.; Hwang, S.O.; Kim, Y.B. Hormone Replacement Therapy and Risks of Various Cancers in Postmenopausal Women with De Novo or a History of Endometriosis. Cancers 2024, 16, 809. https://doi.org/10.3390/cancers16040809

AMA Style

Lee HJ, Lee B, Choi H, Lee M, Lee K, Lee TK, Hwang SO, Kim YB. Hormone Replacement Therapy and Risks of Various Cancers in Postmenopausal Women with De Novo or a History of Endometriosis. Cancers. 2024; 16(4):809. https://doi.org/10.3390/cancers16040809

Chicago/Turabian Style

Lee, Hee Joong, Banghyun Lee, Hangseok Choi, Minkyung Lee, Kyungjin Lee, Tae Kyoung Lee, Sung Ook Hwang, and Yong Beom Kim. 2024. "Hormone Replacement Therapy and Risks of Various Cancers in Postmenopausal Women with De Novo or a History of Endometriosis" Cancers 16, no. 4: 809. https://doi.org/10.3390/cancers16040809

APA Style

Lee, H. J., Lee, B., Choi, H., Lee, M., Lee, K., Lee, T. K., Hwang, S. O., & Kim, Y. B. (2024). Hormone Replacement Therapy and Risks of Various Cancers in Postmenopausal Women with De Novo or a History of Endometriosis. Cancers, 16(4), 809. https://doi.org/10.3390/cancers16040809

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop